PCTA versus medical treatment for non-acute coronary heart disease
Sübutlu məlumatların xülasələri
29.08.2017 • Sonuncu dəyişiklik 29.08.2017
Editors
PTCA may lead to greater reduction in angina, but there is no evidence of improved survival or reduction of subsequent revascularization, though trends do not favour angioplasty.
A systematic review including 6 RCTs with a total of 1904 subjects was abstracted in DARE. The risk ratio for angina was 0.70 (95% CI 0.50 to 0.98), for death 1.32 (95% CI 0.90 to 2.25), for coronary artery bypass graft 1.59 (95% CI 1.09 to 2.32) and repeated angioplasty 1.29 (95% CI 0.71 to 3.36).
Comment: The level of evidency is downgraded by inconsistency (the results were pooled although there was significant heterogeneity) and by imprecise results (limited study size for endstage events).
Ədəbiyyat
- Bucher HC, Hengstler P, Schindler C, Guyatt GH. Percutaneous transluminal coronary angioplasty versus medical treatment for non-acute coronary heart disease: meta-analysis of randomised controlled trials. BMJ 2000 Jul 8;321(7253):73-7.
- .